The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Kura Oncology Inc (KURA)

Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s primary product candidate, ziftomenib, is a selective, reversible and oral small molecule inhibitor which blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene. Co.'s second product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co. is evaluating tipifarnib in multiple solid tumor and hematologic indications.

KURA SEC Filing Email Alerts Service

Company Name:  Kura Oncology Inc
Website:  www.kuraoncology.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding KURA:  23
Total Market Value Held by ETFs:  $196.76M
Total Market Capitalization:  $1.55B
% of Market Cap. Held by ETFs:  12.65%
March 29, 2024    6:51 AM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree KURA Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.86 out of 4)
74th percentile
(ranked higher than approx. 74% of all stocks covered)

Analysts' Target Price:
KURA Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Kura Oncology Inc (KURA) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.